Wednesday, June 11, 2025
EC Approves Santen’s Ryjunea to Slow Progression of Pediatric Myopia
The product is indicated for children aged 3 to 14 years at treatment initiation, with myopia progression of 0.5 D or more per year and severity between –0.5 D and –6.0 D.